New research is showing that an abundance of certain specific types of gut bacteria could be associated with the likelihood of developing Alzheimer's disease.

The World Health Organization recommends against using sugar substitutes to help with weight loss, or to reduce the risk of diet-related diseases such as heart disease and diabetes.

A growing body of evidence suggests that an imbalance of the human gut microbiome is associated with the development of neurodegenerative diseases like Alzheimer’s disease (AD) via neuroinflammatory processes across the gut-brain axis. Now, researchers at the University of Las Vegas have identified 10 bacterial groups associated with Alzheimer’s disease, providing new insights into the relationship between the gut and dementia.

Specific types of gut bacteria and Alzheimer's disease are closely related.

The UNLV team’s analysis found a significant correlation between 10 specific types of gut bacteria and the likelihood of developing Alzheimer’s disease.

Heart Disease is the number one cause of death for women in the United States. And one in three Nevada women have some form of heart disease. Two women share how it affects their lives, and a doctor weighs in on what women should look out for. Plus we’re checking in on the latest going on in Nevada’s Legislative Session, including health-related bills.

The UNLV team’s investigation found a big link between ten particular types of gut bacteria and the chances of getting Alzheimer’s disease. 

The analysis — led by a team of researchers with the Nevada Institute of Personalized Medicine (NIPM) at UNLV and published this spring in the Nature journal Scientific Reports — examined data from dozens of past studies into the belly-brain connection. The results? There’s a strong link between particular kinds of gut bacteria and Alzheimer’s disease.

Could changing your diet play a role in slowing or even preventing the development of dementia? We're one step closer to finding out, thanks to a new UNLV study that bolsters the long-suspected link between gut health and Alzheimer's disease.

Lighthouse Pharmaceuticals, a clinical-stage pharmaceutical company developing therapeutics to alter the course of dementia and other degenerative diseases, announced completion of a Pre-investigational New Drug meeting with the Food and Drug Administration related to the planned Phase 2b clinical study of LHP588 and the formation of its Clinical Advisory Board (CAB). The CAB includes six members with diverse backgrounds and expertise in dementia, Alzheimer’s disease, inflammation, neurodegenerative disorders, and drug development.

A new drug shows promising results in trials, but questions remain about whether benefits outweigh side effects.

Findings suggest that the amyloid-targeting drug candidate slows cognitive decline in some people, but questions remain over its potential side effects